Comparative Pharmacology
Head-to-head clinical analysis: ORTHO NOVUM 7 14 21 versus PIRMELLA 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORTHO NOVUM 7 14 21 versus PIRMELLA 7 7 7.
ORTHO-NOVUM 7/14-21 vs PIRMELLA 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive: suppresses gonadotropin release, inhibits ovulation, thickens cervical mucus, alters endometrial receptivity.
Pirmelevir is a selective inhibitor of the hepatitis C virus (HCV) NS5A protein, essential for viral replication and assembly. It disrupts the double-membrane vesicles where HCV RNA replication occurs.
One tablet containing 0.5 mg norethindrone/0.035 mg ethinyl estradiol (white tablets) on days 1-14, then one tablet containing 1 mg norethindrone/0.035 mg ethinyl estradiol (peach tablets) on days 15-21, then no tablets for 7 days; repeated cycles.
PIRMELLA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.180/0.215/0.250 mg in a triphasic regimen. One tablet daily for 28 days, with 7 inactive tablets.
None Documented
None Documented
Norethindrone: 10-12 hours (terminal), ethinyl estradiol: 13-27 hours (terminal); clinical context: steady state achieved within 5-7 days
Terminal elimination half-life: 8-10 hours. Clinically, steady-state reached in 2-3 days.
Renal: ~40% as glucuronide and sulfate conjugates; Fecal: ~20%; Biliary: minor
Renal: 70% unchanged; fecal: 30% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive